New data, analyses take some of the shine off Merck’s Covid pill
New data, in addition to analyses by scientists at the Food and Drug Administration, may take some of the shine off Merck’s experimental Covid pill, molnupiravir.
On Friday, the drug maker released full results from its study of the pill, molnupiravir, showing it reduced the risk of hospitalization by 30%, down from a decrease of 50% seen in an earlier analysis. In the 1,433-patient study, fewer patients died when they received the treatment. There were nine deaths in the placebo group in the final analysis, and one in the molnupiravir group.
Read Original Article: New data, analyses take some of the shine off Merck’s Covid pill »
